Abstract
The tumor microenvironment (TME) and its complex role in cancer progression have been hotspots of cancer research in recent years. Ascites, which occurs frequently in patients with ovarian cancer especially in advanced stages, represents a unique TME. Malignant ascites contains abundant cellular and acellular components that play important roles in tumorigenesis, growth, metastasis, and chemoresistance of ovarian cancer through complex molecular mechanisms and signaling pathways. As a valuable liquid biopsy sample, ascites fluid is also of great significance for the prognostic analysis of ovarian cancer. The components of ovarian cancer ascites are generally considered to comprise tumor-promoting factors; however, in recent years studies have found that ascites also contains tumor-suppressing factors, raising new perspectives on interactions between ascites and tumors. Malignant ascites directly constitutes the ovarian cancer microenvironment, therefore, the study of its components will aid in the development of new therapeutic strategies. This article reviews the current research on tumor-promoting and tumor-suppressing factors and molecular mechanisms of their actions in ovarian cancer-derived ascites and therapeutic strategies targeting ascites, which may provide references for the development of novel therapeutic targets for ovarian cancer in the future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198:999–1011. https://doi.org/10.1016/j.jamcollsurg.2004.01.035
Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, Wagner U, Muller-Brusselbach S, Reinartz S, Muller R (2017) Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genom 18:243. https://doi.org/10.1186/s12864-017-3630-9
Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G (2018) Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol 53:265–281. https://doi.org/10.1016/j.semcancer.2018.10.002
Arend RC, Scalise CB, Gordon ER, Davis AM, Foxall ME, Johnston BE, Crossman DK, Cooper SJ (2022) Metabolic alterations and WNT signaling impact immune response in HGSOC. Clin Cancer Res 28:1433–1445. https://doi.org/10.1158/1078-0432.CCR-21-2984
Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A (2019) Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer. Front Immunol 10:1273. https://doi.org/10.3389/fimmu.2019.01273
Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T et al (2008) Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol 108:421–427. https://doi.org/10.1016/j.ygyno.2007.10.018
Bekes I, Friedl TW, Kohler T, Mobus V, Janni W, Wockel A, Wulff C (2016) Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer 15:13. https://doi.org/10.1186/s12943-016-0497-3
Bhattacharya P, Sett S, Maity P (2001) Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice. J Exp Clin Cancer Res 20:599–607.
Bortot B, Apollonio M, Rampazzo E, Valle F, Brucale M, Ridolfi A, Ura B, Addobbati R, Di Lorenzo G, Romano F et al (2021) Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix. Mol Oncol 15:3596-3614. https://doi.org/10.1002/1878-0261.13110
Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA et al (2017) Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res 23:1710–1721. https://doi.org/10.1158/1078-0432.CCR-15-2851
Brencicova E, Jagger AL, Evans HG, Georgouli M, Laios A, Attard Montalto S, Mehra G, Spencer J, Ahmed AA, Raju-Kankipati S et al (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS ONE 12:e0175712. https://doi.org/10.1371/journal.pone.0175712
Brown S, Pineda CM, Xin T, Boucher J, Suozzi KC, Park S, Matte-Martone C, Gonzalez DG, Rytlewski J, Beronja S et al (2017) Correction of aberrant growth preserves tissue homeostasis. Nature 548:334–337. https://doi.org/10.1038/nature23304
Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D (2012) Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31:2521–2534. https://doi.org/10.1038/onc.2011.429
Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:847. https://doi.org/10.3389/fimmu.2018.00847
Chen RR, Yung MMH, Xuan Y, Zhan S, Leung LL, Liang RR, Leung THY, Yang H, Xu D, Sharma R et al (2019) Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol 2:281. https://doi.org/10.1038/s42003-019-0508-1
Chen P, Hsu WH, Chang A, Tan Z, Lan Z, Zhou A, Spring DJ, Lang FF, Wang YA, DePinho RA (2020) Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov 10:371–381. https://doi.org/10.1158/2159-8290.CD-19-0400
Cohen M, Petignat P (2014) The bright side of ascites in ovarian cancer. Cell Cycle 13:2319. https://doi.org/10.4161/cc.29951
Condamine T, Ramachandran I, Youn JI, Gabrilovich DI (2015) Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66:97–110. https://doi.org/10.1146/annurev-med-051013-052304
Correa RJ, Valdes YR, Shepherd TG, DiMattia GE (2015) Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro. J Ovarian Res 8:52. https://doi.org/10.1186/s13048-015-0182-y
Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW et al (2019) Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology 106:244–251. https://doi.org/10.1016/j.psyneuen.2019.04.007
Cuneo MG, Szeto A, Schrepf A, Thaker PH, Goodheart M, Cole SW, Sood AK, McCabe PM, Mendez AJ, Lutgendorf SK (2021) Positive psychosocial factors and oxytocin in the ovarian tumor microenvironment. Psychosom Med 83:417–422. https://doi.org/10.1097/PSY.0000000000000935
Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G et al (2004a) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64:5535–5538. https://doi.org/10.1158/0008-5472.CAN-04-1272
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al (2004b) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. https://doi.org/10.1038/nm1093
Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z et al (2019) Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun 10:3000. https://doi.org/10.1038/s41467-019-10979-3
da Silva RF, Yoshida A, Cardozo DM, Jales RM, Paust S, Derchain S, Guimaraes F (2017) Natural killer cells response to IL-2 stimulation is distinct between ascites with the presence or absence of malignant cells in ovarian cancer patients. Int J Mol Sci 18:856. https://doi.org/10.3390/ijms18050856
Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, Roy KK, Singh N, Vanamail P (2018) Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin Chim Acta 482:27–32. https://doi.org/10.1016/j.cca.2018.03.019
de Bruyn M, Wiersma VR, Wouters MC, Samplonius DF, Klip HG, Helfrich W, Nijman HW, Eggleton P, Bremer E (2015) CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology 4:e999536. https://doi.org/10.1080/2162402X.2014.999536
Di Modica M, Gargari G, Regondi V, Bonizzi A, Arioli S, Belmonte B, De Cecco L, Fasano E, Bianchi F, Bertolotti A et al (2021) Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer. Cancer Res 81:2195–2206. https://doi.org/10.1158/0008-5472.CAN-20-1659
Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, Nortier JW, Welters MJ, Kroep JR, van der Burg SH (2013) Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res 73:2480–2492. https://doi.org/10.1158/0008-5472.CAN-12-3542
Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, Sturken C, Oliveira-Ferrer L (2021) Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. Mol Oncol 15:3578–3595. https://doi.org/10.1002/1878-0261.13028
Dolinschek R, Hingerl J, Benge A, Zafiu C, Schuren E, Ehmoser EK, Lossner D, Reuning U (2021) Constitutive activation of integrin alphavbeta3 contributes to anoikis resistance of ovarian cancer cells. Mol Oncol 15:503–522. https://doi.org/10.1002/1878-0261.12845
Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N et al (2007) Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110:4319–4330. https://doi.org/10.1182/blood-2007-02-072587
Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P (2009) Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 125:367–373. https://doi.org/10.1002/ijc.24401
Fabris L, Sato K, Alpini G, Strazzabosco M (2021) The tumor microenvironment in cholangiocarcinoma progression. Hepatology 73(Suppl 1):75–85. https://doi.org/10.1002/hep.31410
Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D (2018) Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer Res 78:631–644. https://doi.org/10.1158/0008-5472.CAN-17-1492
Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, Bernardini MQ, Kollara A, Brown TJ, Murphy KJ (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103. https://doi.org/10.1155/2014/367103
Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS et al (2017) IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol 145:453–461. https://doi.org/10.1016/j.ygyno.2017.02.028
Feng Y, Xiao M, Zhang Z, Cui R, Jiang X, Wang S, Bai H, Liu C, Zhang Z (2020) Potential interaction between lysophosphatidic acid and tumor-associated macrophages in ovarian carcinoma. J Inflamm (lond) 17:23. https://doi.org/10.1186/s12950-020-00254-4
Ferraresi A, Esposito A, Girone C, Vallino L, Salwa A, Ghezzi I, Thongchot S, Vidoni C, Dhanasekaran DN, Isidoro C (2021) Resveratrol contrasts LPA-induced ovarian cancer cell migration and platinum resistance by rescuing hedgehog-mediated autophagy. Cells 10:3213. https://doi.org/10.3390/cells10113213
Fogg KC, Olson WR, Miller JN, Khan A, Renner C, Hale I, Weisman PS, Kreeger PK (2019) Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway. Cancer Lett 458:92–101. https://doi.org/10.1016/j.canlet.2019.05.029
Fogg KC, Renner CM, Christian H, Walker A, Marty-Santos L, Khan A, Olson WR, Parent C, O’Shea A, Wellik DM et al (2020) Ovarian cells have increased proliferation in response to heparin-binding epidermal growth factor as collagen density increases. Tissue Eng Part A 26:747–758. https://doi.org/10.1089/ten.tea.2020.0001
Ford CE, Werner B, Hacker NF, Warton K (2020) The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 123:9–16. https://doi.org/10.1038/s41416-020-0875-x
Fujikake K, Kajiyama H, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Suzuki S, Niimi K, Sakata J, Mitsui H et al (2018) A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer. Oncol Rep 39:193–200. https://doi.org/10.3892/or.2017.6104
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103. https://doi.org/10.1038/nm1096-1096
Galbo PM Jr, Zang X, Zheng D (2021) Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res 27:2636–2647. https://doi.org/10.1158/1078-0432.CCR-20-4226
Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C et al (2019) Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med 216:688–703. https://doi.org/10.1084/jem.20180765
Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D et al (2012) VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 107:1869–1875. https://doi.org/10.1038/bjc.2012.468
Gening SO, Abakumova TV, Antoneeva II, Rizvanov AA, Gening TP, Gafurbaeva DU (2021) Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients. Klin Lab Diagn 66:297–303. https://doi.org/10.51620/0869-2084-2021-66-5-297-303
Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875–2884
Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B (2011) IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2:29. https://doi.org/10.3389/fimmu.2011.00029
Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, Wulff C (2012) VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol 127:210–216. https://doi.org/10.1016/j.ygyno.2012.05.002
Hinshaw DC, Shevde LA (2019) The tumor microenvironment innately modulates cancer progression. Cancer Res 79:4557–4566. https://doi.org/10.1158/0008-5472.CAN-18-3962
Hoogstad-van Evert JS, Maas RJ, van der Meer J, Cany J, van der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L et al (2018) Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget 9:34810–34820. https://doi.org/10.18632/oncotarget.26199
Hopkins D, Sanchez H, Berwin B, Wilkinson-Ryan I (2021) Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer. Transl Oncol 14:101217. https://doi.org/10.1016/j.tranon.2021.101217
Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB (2001) Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93:762–768. https://doi.org/10.1093/jnci/93.10.762
Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH (2013) Clinical significance of ascites in epithelial ovarian cancer. Neoplasma 60:546–552. https://doi.org/10.4149/neo_2013_071
Huang CT, Chang MC, Chen YL, Chen TC, Chen CA, Cheng WF (2015) Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation. Cancer Lett 359:117–126. https://doi.org/10.1016/j.canlet.2015.01.007
Huang X, Zhou J, Tang R, Han S, Zhou X (2018) Potential significance of peptidome in human ovarian cancer for patients with ascites. Int J Gynecol Cancer 28:355–362. https://doi.org/10.1097/IGC.0000000000001166
Imamura Y, Tashiro H, Tsend-Ayush G, Haruta M, Dashdemberel N, Komohara Y, Tsuboki J, Takaishi K, Ohba T, Nishimura Y et al (2018) Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta. Cancer Sci 109:3403–3410. https://doi.org/10.1111/cas.13775
Inoue N, Yamazaki Z, Oda T, Sugiura M, Wada T (1977) Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23:699–702
Iyoshi S, Yoshihara M, Nakamura K, Sugiyama M, Koya Y, Kitami K, Uno K, Mogi K, Tano S, Tomita H et al (2021) Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer. Int J Cancer 149:1961–1972. https://doi.org/10.1002/ijc.33770
Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P et al (2020) A single-cell landscape of high-grade serous ovarian cancer. Nat Med 26:1271–1279. https://doi.org/10.1038/s41591-020-0926-0
Jandu N, Richardson M, Singh G, Hirte H, Hatton MW (2006) Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int J Gynecol Cancer 16:1536–1544. https://doi.org/10.1111/j.1525-1438.2006.00624.x
Ji Z, Tian W, Gao W, Zang R, Wang H, Yang G (2021) Cancer-associated fibroblast-derived interleukin-8 promotes ovarian cancer cell stemness and malignancy through the Notch3-mediated signaling. Front Cell Dev Biol 9:684505. https://doi.org/10.3389/fcell.2021.684505
Jiang YX, Siu MK, Wang JJ, Mo XT, Leung TH, Chan DW, Cheung AN, Ngan HY, Chan KK (2020) Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer. Br J Cancer 123:275–287. https://doi.org/10.1038/s41416-020-0865-z
Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M (2017) Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor receptor 2-expressing regulatory T cells. Front Immunol 8:1482. https://doi.org/10.3389/fimmu.2017.01482
Kan T, Wang W, Ip PP, Zhou S, Wong AS, Wang X, Yang M (2020) Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 39:4227–4240. https://doi.org/10.1038/s41388-020-1288-2
Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M (2014) Clock genes: their role in colorectal cancer. World J Gastroenterol 20:1986–1992. https://doi.org/10.3748/wjg.v20.i8.1986
Kathawala RJ, Gupta P, Ashby CR Jr, Chen ZS (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 18:1–17. https://doi.org/10.1016/j.drup.2014.11.002
Kawata Y, Nagasaka K, Matsumoto Y, Oda K, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Arimoto T, Osuga Y et al (2019) Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. Int J Clin Oncol 24:420–427. https://doi.org/10.1007/s10147-018-1371-7
Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A et al (2020) Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov 10:1330–1351. https://doi.org/10.1158/2159-8290.CD-19-1384
Kim S, Gwak H, Kim HS, Kim B, Dhanasekaran DN, Song YS (2016) Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro. Oncotarget 7:83148–83159. https://doi.org/10.18632/oncotarget.13074
Kim S, Han Y, Kim SI, Lee J, Jo H, Wang W, Cho U, Park WY, Rando TA, Dhanasekaran DN et al (2021) Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer. Mol Carcinog 60:297–312. https://doi.org/10.1002/mc.23289
Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273–282. https://doi.org/10.1038/nrc3432
Klapdor R, Wang S, Hacker U, Buning H, Morgan M, Dork T, Hillemanns P, Schambach A (2017) Improved killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy. Hum Gene Ther 28:886–896. https://doi.org/10.1089/hum.2017.168
Kobayashi M, Wood PA, Hrushesky WJ (2002) Circadian chemotherapy for gynecological and genitourinary cancers. Chronobiol Int 19:237–251. https://doi.org/10.1081/cbi-120002600
Kotrbova A, Ovesna P, Gybel T, Radaszkiewicz T, Bednarikova M, Hausnerova J, Jandakova E, Minar L, Crha I, Weinberger V et al (2020) WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer. Theranostics 10:537–552. https://doi.org/10.7150/thno.37423
Krishnapriya S, Sidhanth C, Manasa P, Sneha S, Bindhya S, Nagare RP, Ramachandran B, Vishwanathan P, Murhekar K, Shirley S et al (2019) Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Angiogenesis 22:441–455. https://doi.org/10.1007/s10456-019-09669-x
Krugmann J, Schwarz CL, Melcher B, Sterlacci W, Ozalinskaite A, Lermann J, Agaimy A, Vieth M (2019) Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006–2015. Arch Gynecol Obstet 299:515–523. https://doi.org/10.1007/s00404-018-4952-9
Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ et al (2017) IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77:6667–6678. https://doi.org/10.1158/0008-5472.CAN-17-0740
Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, Zheng M, Zhang YN, Feng YL, Liu Q et al (2018) Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol 19:1239–1246. https://doi.org/10.1016/S1470-2045(18)30349-8
Landskron J, Helland O, Torgersen KM, Aandahl EM, Gjertsen BT, Bjorge L, Tasken K (2015) Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother 64:337–347. https://doi.org/10.1007/s00262-014-1636-6
Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393:1240–1253. https://doi.org/10.1016/S0140-6736(18)32552-2
Liu Y, Tang J, Liu D, Zhang L, He Y, Li J, Gao L, Tang D, Jin X, Kong D (2018) Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance. Cell Death Dis 9:419. https://doi.org/10.1038/s41419-018-0449-5
Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y et al (2017) Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov 7:522–538. https://doi.org/10.1158/2159-8290.CD-16-0932
Maas RJ, Hoogstad-van Evert JS, Van der Meer JM, Mekers V, Rezaeifard S, Korman AJ, de Jonge PK, Cany J, Woestenenk R, Schaap NP et al (2020) TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology 9:1843247. https://doi.org/10.1080/2162402X.2020.1843247
McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP et al (2012) BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol 25:740–750. https://doi.org/10.1038/modpathol.2011.211
Mikula-Pietrasik J, Uruski P, Matuszkiewicz K, Szubert S, Moszynski R, Szpurek D, Sajdak S, Tykarski A, Ksiazek K (2016) Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol (dordr) 39:473–481. https://doi.org/10.1007/s13402-016-0289-1
Newsted D, Banerjee S, Watt K, Nersesian S, Truesdell P, Blazer LL, Cardarelli L, Adams JJ, Sidhu SS, Craig AW (2019) Blockade of TGF-beta signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology 8:e1539613. https://doi.org/10.1080/2162402X.2018.1539613
Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH et al (2020) Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest 130:3865–3884. https://doi.org/10.1172/JCI131859
Onallah H, Davidson B, Reich R (2019) Diverse effects of lysophosphatidic acid receptors on ovarian cancer signaling pathways. J Oncol 2019:7547469. https://doi.org/10.1155/2019/7547469
Onuma T, Mizutani T, Fujita Y, Yamada S, Yoshida Y (2021) Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer. J Trace Elem Med Biol 68:126865. https://doi.org/10.1016/j.jtemb.2021.126865
Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719–734. https://doi.org/10.1016/j.ccr.2014.04.005
Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H et al (2022) Patient-derived ovarian cancer spheroids rely on PI3K-AKT signaling addiction for cancer stemness and chemoresistance. Cancers (basel) 14:958. https://doi.org/10.3390/cancers14040958
Pegtel DM, Gould SJ (2019) Exosomes. Annu Rev Biochem 88:487–514. https://doi.org/10.1146/annurev-biochem-013118-111902
Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D, Huang X, Yang Y (2019) Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest 129:5151–5162. https://doi.org/10.1172/JCI128644
Pi R, Yang Y, Hu X, Li H, Shi H, Liu Y, Wang X, Tong A, Lu T, Wei Y et al (2021) Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. Cancer Lett 523:72–81. https://doi.org/10.1016/j.canlet.2021.09.017
Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Jaras M et al (2016) Core circadian clock genes regulate leukemia stem cells in AML. Cell 165:303–316. https://doi.org/10.1016/j.cell.2016.03.015
Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN (2019) Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Lett 442:464–474. https://doi.org/10.1016/j.canlet.2018.11.023
Rafehi S, Ramos Valdes Y, Bertrand M, McGee J, Prefontaine M, Sugimoto A, DiMattia GE, Shepherd TG (2016) TGFbeta signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocr Relat Cancer 23:147–159. https://doi.org/10.1530/ERC-15-0383
Ray U, Roy SS, Chowdhury SR (2017) Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1. Cell Physiol Biochem 41:795–805. https://doi.org/10.1159/000458744
Ray U, Jung DB, Jin L, Xiao Y, Dasari S, Sarkar Bhattacharya S, Thirusangu P, Staub JK, Roy D, Roy B et al (2022) Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer. Cancer Res 82:1038–1054. https://doi.org/10.1158/0008-5472.CAN-21-0622
Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, Nockher WA, Nist A, Stiewe T, Jansen JM et al (2016) A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol 17:108. https://doi.org/10.1186/s13059-016-0956-6
Reinartz S, Lieber S, Pesek J, Brandt DT, Asafova A, Finkernagel F, Watzer B, Nockher WA, Nist A, Stiewe T et al (2019) Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. Mol Oncol 13:185–201. https://doi.org/10.1002/1878-0261.12396
Ren B, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y (2018) Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer 17:108. https://doi.org/10.1186/s12943-018-0858-1
Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW et al (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735–747. https://doi.org/10.1016/j.ccr.2014.04.021
Rodrigues ISS, Martins-Filho A, Micheli DC, Lima CA, Tavares-Murta BM, Murta EFC, Nomelini RS (2020) IL-6 and IL-8 as prognostic factors in peritoneal fluid of ovarian cancer. Immunol Invest 49:510–521. https://doi.org/10.1080/08820139.2019.1691222
Rozman P, Svajger U (2018) The tolerogenic role of IFN-gamma. Cytokine Growth Factor Rev 41:40–53. https://doi.org/10.1016/j.cytogfr.2018.04.001
Rynne-Vidal A, Au-Yeung CL, Jimenez-Heffernan JA, Perez-Lozano ML, Cremades-Jimeno L, Barcena C, Cristobal-Garcia I, Fernandez-Chacon C, Yeung TL, Mok SC et al (2017) Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol 242:140–151. https://doi.org/10.1002/path.4889
Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P et al (2017) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36:168–181. https://doi.org/10.1038/onc.2016.197
Sanchez-Gonzalez I, Bobien A, Molnar C, Schmid S, Strotbek M, Boerries M, Busch H, Olayioye MA (2020) miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. Cancer Res 80:1330–1341. https://doi.org/10.1158/0008-5472.CAN-19-1934
Shafi AA, Knudsen KE (2019) Cancer and the circadian clock. Cancer Res 79:3806–3814. https://doi.org/10.1158/0008-5472.CAN-19-0566
Shender V, Arapidi G, Butenko I, Anikanov N, Ivanova O, Govorun V (2019) Peptidome profiling dataset of ovarian cancer and non-cancer proximal fluids: ascites and blood sera. Data Brief 22:557–562. https://doi.org/10.1016/j.dib.2018.12.056
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33. https://doi.org/10.3322/caac.21654
Singel KL, Grzankowski KS, Khan A, Grimm MJ, D’Auria AC, Morrell K, Eng KH, Hylander B, Mayor PC, Emmons TR et al (2019) Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. Br J Cancer 120:207–217. https://doi.org/10.1038/s41416-018-0339-8
Sjoquist KM, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S, Goh J, Bowtell D, Harrison M, Friedlander ML (2021) REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecol Oncol 161:374–381. https://doi.org/10.1016/j.ygyno.2021.02.002
Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X (2009) Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 15:492–501. https://doi.org/10.1158/1078-0432.CCR-08-1945
Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J et al (2020) Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun 11:6298. https://doi.org/10.1038/s41467-020-20140-0
Soysal SD, Tzankov A, Muenst SE (2015) Role of the tumor microenvironment in breast cancer. Pathobiology 82:142–152. https://doi.org/10.1159/000430499
Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, Wagner U, Graumann J, Muller R, Reinartz S (2020) Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis 11:249. https://doi.org/10.1038/s41419-020-2438-8
Swamy NS, Devaraj VR, Premalatha CS, Pallavi VR, Sagar BC, Shinde DD, Gawari R (2022) Metabolic reprogramming and lipophagy mediates survival of ascites derived metastatic ovarian cancer cells. Asian Pac J Cancer Prev 23:1699–1709. https://doi.org/10.31557/APJCP.2022.23.5.1699
Tang M, Liu B, Bu X, Zhao P (2018) Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment. Cancer Sci 109:1309–1318. https://doi.org/10.1111/cas.13567
Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL, Oelke M, Schneck JP, Webb TJ (2016) VEGF potentiates GD3-mediated immunosuppression by human ovarian cancer cells. Clin Cancer Res 22:4249–4258. https://doi.org/10.1158/1078-0432.CCR-15-2518
Tonetti CR, de Souza-Araujo CN, Yoshida A, da Silva RF, Alves PCM, Mazzola TN, Derchain S, Fernandes LGR, Guimaraes F (2021) Ovarian cancer-associated ascites have high proportions of cytokine-responsive CD56bright NK cells. Cells 10:1702. https://doi.org/10.3390/cells10071702
Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, Defusco A, Plager S, Warden S, Huang D et al (2017) Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal 10:eaaf8608. https://doi.org/10.1126/scisignal.aaf8608
Tuppurainen L, Sallinen H, Karvonen A, Valkonen E, Laakso H, Liimatainen T, Hytonen E, Hamalainen K, Kosma VM, Anttila M et al (2017) Combined gene therapy using AdsVEGFR2 and AdsTie2 with chemotherapy reduces the growth of human ovarian cancer and formation of ascites in mice. Int J Gynecol Cancer 27:879–886. https://doi.org/10.1097/IGC.0000000000000973
Uddin MM, Gaire B, Vancurova I (2020) Interleukin-8 induces proliferation of ovarian cancer cells in 3D spheroids. Methods Mol Biol 2108:117–124. https://doi.org/10.1007/978-1-0716-0247-8_10
Ullah M, Azazzen D, Kaci R, Benabbou N, Pujade Lauraine E, Pocard M, Mirshahi M (2019) High expression of HLA-G in ovarian carcinomatosis: the role of Interleukin-1beta. Neoplasia 21:331–342. https://doi.org/10.1016/j.neo.2019.01.001
Uppendahl LD, Felices M, Bendzick L, Ryan C, Kodal B, Hinderlie P, Boylan KLM, Skubitz APN, Miller JS, Geller MA (2019) Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. Gynecol Oncol 153:149–157. https://doi.org/10.1016/j.ygyno.2019.01.006
Uruski P, Mikula-Pietrasik J, Pakula M, Budkiewicz S, Drzewiecki M, Gaiday AN, Wierzowiecka M, Naumowicz E, Moszynski R, Tykarski A et al (2021) Malignant ascites promote adhesion of ovarian cancer cells to peritoneal mesothelium and fibroblasts. Int J Mol Sci 22:4222. https://doi.org/10.3390/ijms22084222
Vlaming M, Bilemjian V, Freile JA, Lourens HJ, van Rooij N, Huls G, van Meerten T, de Bruyn M, Bremer E (2021) CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. Sci Rep 11:20499. https://doi.org/10.1038/s41598-021-00007-0
Wang Y, Qian R, Sun N, Lu C, Chen Z, Hua L (2015) Circadian gene hClock enhances proliferation and inhibits apoptosis of human colorectal carcinoma cells in vitro and in vivo. Mol Med Rep 11:4204–4210. https://doi.org/10.3892/mmr.2015.3247
Wang HY, Zhao R, Ren H, Zou MJ, Zhang J, Zhang Y (2017) The expression and association of CD14(+) HLA-DR(Low/−) myeloid-derived suppressor cell-like cells and interleukin-1beta in ovarian cancer. Zhonghua Yi Xue Za Zhi 97:2663–2669. https://doi.org/10.3760/cma.j.issn.0376-2491.2017.34.005
Wang XY, Zhou YC, Wang Y, Liu YY, Wang YX, Chen DD, Fan Y (2020a) miR-149 contributes to resistance of 5-FU in gastric cancer via targeting TREM2 and regulating beta-catenin pathway. Biochem Biophys Res Commun 532:329–335. https://doi.org/10.1016/j.bbrc.2020.05.135
Wang W, Wu J, Mukherjee A, He T, Wang XY, Ma Y, Fang X (2020b) Lysophosphatidic acid induces tumor necrosis factor-alpha to regulate a pro-inflammatory cytokine network in ovarian cancer. FASEB J 34:13935–13948. https://doi.org/10.1096/fj.202001136R
Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger L, De Vries IJM (2018) Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites. Front Immunol 9:3156. https://doi.org/10.3389/fimmu.2018.03156
Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W, Lu X (2016) Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol 37:6581–6588. https://doi.org/10.1007/s13277-015-4538-0
Wertel I, Surowka J, Polak G, Barczynski B, Bednarek W, Jakubowicz-Gil J, Bojarska-Junak A, Kotarski J (2015) Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol 36:4811–4817. https://doi.org/10.1007/s13277-015-3133-8
Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Muller R (2017) The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol 7:24. https://doi.org/10.3389/fonc.2017.00024
Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H (2017) Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget 8:76843–76856. https://doi.org/10.18632/oncotarget.20164
Wu SZ, Roden DL, Wang C, Holliday H, Harvey K, Cazet AS, Murphy KJ, Pereira B, Al-Eryani G, Bartonicek N et al (2020) Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J 39:e104063. https://doi.org/10.15252/embj.2019104063
Yamamoto K, Nagao S, Tsu T, Matsushima T, Ishido Y, Narita M, Suzuki K, Nakazawa H, Shibutani T, Jimi T et al (2021) Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study. J Obstet Gynaecol Res 47:1536–1543. https://doi.org/10.1111/jog.14670
Yang Y, Cao Y (2022) The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2022.03.011
Yang L, Zhang X, Ma Y, Zhao X, Li B, Wang H (2017) Ascites promotes cell migration through the repression of miR-125b in ovarian cancer. Oncotarget 8:51008–51015. https://doi.org/10.18632/oncotarget.16846
Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7:10541. https://doi.org/10.1038/s41598-017-10940-8
Yoshida M, Taguchi A, Kawana K, Ogishima J, Adachi K, Kawata A, Nakamura H, Sato M, Fujimoto A, Inoue T et al (2018) Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity. Int J Oncol 53:1580–1590. https://doi.org/10.3892/ijo.2018.4504
Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630–1642. https://doi.org/10.1093/jnci/djn378
Yu X, Zhang Y, Chen H (2016) LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer 16:846. https://doi.org/10.1186/s12885-016-2865-1
Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C (1998) Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16:1861–1868. https://doi.org/10.1200/JCO.1998.16.5.1861
Zhan N, Dong WG, Wang J (2016) The clinical significance of vascular endothelial growth factor in malignant ascites. Tumour Biol 37:3719–3725. https://doi.org/10.1007/s13277-015-4198-0
Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA (2018) LY2157299 monohydrate, a TGF-betaR1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer. Cancers (basel) 10:260. https://doi.org/10.3390/cancers10080260
Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M et al (2019) Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut 68:2019–2031. https://doi.org/10.1136/gutjnl-2019-318912
Zhu Q, Wu X, Wu Y, Wang X (2016) Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep 36:3472–3478. https://doi.org/10.3892/or.2016.5136
Acknowledgements
This study was financially supported by the National Natural Science Foundation of China (81872126), Jiangsu Provincial Key Research and Development Program (BE2019621), 333 project of Jiangsu Province (Xuemei Jia).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors report no conflicts of interest in this work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Geng, Z., Pan, X., Xu, J. et al. Friend and foe: the regulation network of ascites components in ovarian cancer progression. J. Cell Commun. Signal. 17, 391–407 (2023). https://doi.org/10.1007/s12079-022-00698-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-022-00698-8